1. PTH-157 The Introduction of Biosimilar Infliximab (CT-P13) through A Managed Switching Programme Generates Significant Cost Savings with High Levels of Patient Satisfaction. (17th August 2016) Authors: Rahmany, S; Cotton, S; Garnish, S; McCabe, L; Brown, M; Saich, R; Lloyd, D; Gordon, JN Journal: Gut Issue: Volume 65(2016)Supplement 1 Page Start: A297 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PTU-073 In Patients with IBD Switching from Originator Infliximab (Remicade) to Biosimilar Infliximab (CT-P13) Is Safe and Effective. (17th August 2016) Authors: Rahmany, S; Cotton, S; Garnish, S; Brown, M; Saich, R; Lloyd, D; Gordon, JN Journal: Gut Issue: Volume 65(2016)Supplement 1 Page Start: A89 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PTH-081 Colorectal cancer in inflammatory bowel disease – is surveillance working?. (22nd June 2015) Authors: Akbar, T; Rahmany, S; Harris, R; Cotton, S; McCabe, L-A; Lloyd, DA; Gordon, JN Journal: Gut Issue: Volume 64(2015)Supplement 1 Page Start: A442 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P389 Switching infliximab to subcutaneous from intravenous therapy (SWIMSUIT) – A prospective, real-world, single centre, phase IV interventional study. (30th January 2023) Authors: Rahmany, S; Young, D; Moyses, H; Gonclaves, J; Latter, S; Cummings, F Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i522 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗